Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

Stefan Faderl, Srdan Verstovsek, Jorge Cortes, Farhad Ravandi, Miloslav Beran, Guillermo Garcia-Manero, Alessandra Ferrajoli, Zeev Estrov, Susan O'Brien, Charles Koller, Francis J. Giles, William Wierda, Monica Kwari, Hagop M. Kantarjian

Research output: Contribution to journalArticle

Abstract

Outcome of patients with acute myeloid leukemia (AML) who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse. We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML. Clofarabine was given at 40 mg/m2 as a 1-hour intravenous infusion for 5 days (days 2 to 6) followed 4 hours later by cytarabine at 1 g/m2/d as a 2-hour intravenous infusion for 5 days (days 1 to 5). Of 60 patients, 29 (48%) had secondary AML, 30 (50%) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25%]), and 11 (21%) showed FLT3 abnormalities. The overall response (OR) rate was 60% (52% CR, 8% CRp). Four patients (7%) died during induction. Adverse events were mainly grade 2 or lower and included diarrhea, nausea, vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-related facial flushing and headaches. Myelosuppression was common. Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation.

Original languageEnglish (US)
Pages (from-to)45-51
Number of pages7
JournalBlood
Volume108
Issue number1
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Intravenous Infusions
Therapeutics
Liver
Abnormal Karyotype
Monosomy
Skin
Mucositis
Survival
Nausea
Vomiting
Headache
clofarabine
Diarrhea
Recurrence

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. / Faderl, Stefan; Verstovsek, Srdan; Cortes, Jorge; Ravandi, Farhad; Beran, Miloslav; Garcia-Manero, Guillermo; Ferrajoli, Alessandra; Estrov, Zeev; O'Brien, Susan; Koller, Charles; Giles, Francis J.; Wierda, William; Kwari, Monica; Kantarjian, Hagop M.

In: Blood, Vol. 108, No. 1, 01.07.2006, p. 45-51.

Research output: Contribution to journalArticle

Faderl, S, Verstovsek, S, Cortes, J, Ravandi, F, Beran, M, Garcia-Manero, G, Ferrajoli, A, Estrov, Z, O'Brien, S, Koller, C, Giles, FJ, Wierda, W, Kwari, M & Kantarjian, HM 2006, 'Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older', Blood, vol. 108, no. 1, pp. 45-51. https://doi.org/10.1182/blood-2005-08-3294
Faderl, Stefan ; Verstovsek, Srdan ; Cortes, Jorge ; Ravandi, Farhad ; Beran, Miloslav ; Garcia-Manero, Guillermo ; Ferrajoli, Alessandra ; Estrov, Zeev ; O'Brien, Susan ; Koller, Charles ; Giles, Francis J. ; Wierda, William ; Kwari, Monica ; Kantarjian, Hagop M. / Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. In: Blood. 2006 ; Vol. 108, No. 1. pp. 45-51.
@article{f86fe164f1f44f5ea67c8b20ed097bc9,
title = "Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older",
abstract = "Outcome of patients with acute myeloid leukemia (AML) who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse. We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML. Clofarabine was given at 40 mg/m2 as a 1-hour intravenous infusion for 5 days (days 2 to 6) followed 4 hours later by cytarabine at 1 g/m2/d as a 2-hour intravenous infusion for 5 days (days 1 to 5). Of 60 patients, 29 (48{\%}) had secondary AML, 30 (50{\%}) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25{\%}]), and 11 (21{\%}) showed FLT3 abnormalities. The overall response (OR) rate was 60{\%} (52{\%} CR, 8{\%} CRp). Four patients (7{\%}) died during induction. Adverse events were mainly grade 2 or lower and included diarrhea, nausea, vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-related facial flushing and headaches. Myelosuppression was common. Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation.",
author = "Stefan Faderl and Srdan Verstovsek and Jorge Cortes and Farhad Ravandi and Miloslav Beran and Guillermo Garcia-Manero and Alessandra Ferrajoli and Zeev Estrov and Susan O'Brien and Charles Koller and Giles, {Francis J.} and William Wierda and Monica Kwari and Kantarjian, {Hagop M.}",
year = "2006",
month = "7",
day = "1",
doi = "10.1182/blood-2005-08-3294",
language = "English (US)",
volume = "108",
pages = "45--51",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

AU - Faderl, Stefan

AU - Verstovsek, Srdan

AU - Cortes, Jorge

AU - Ravandi, Farhad

AU - Beran, Miloslav

AU - Garcia-Manero, Guillermo

AU - Ferrajoli, Alessandra

AU - Estrov, Zeev

AU - O'Brien, Susan

AU - Koller, Charles

AU - Giles, Francis J.

AU - Wierda, William

AU - Kwari, Monica

AU - Kantarjian, Hagop M.

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Outcome of patients with acute myeloid leukemia (AML) who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse. We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML. Clofarabine was given at 40 mg/m2 as a 1-hour intravenous infusion for 5 days (days 2 to 6) followed 4 hours later by cytarabine at 1 g/m2/d as a 2-hour intravenous infusion for 5 days (days 1 to 5). Of 60 patients, 29 (48%) had secondary AML, 30 (50%) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25%]), and 11 (21%) showed FLT3 abnormalities. The overall response (OR) rate was 60% (52% CR, 8% CRp). Four patients (7%) died during induction. Adverse events were mainly grade 2 or lower and included diarrhea, nausea, vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-related facial flushing and headaches. Myelosuppression was common. Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation.

AB - Outcome of patients with acute myeloid leukemia (AML) who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse. We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML. Clofarabine was given at 40 mg/m2 as a 1-hour intravenous infusion for 5 days (days 2 to 6) followed 4 hours later by cytarabine at 1 g/m2/d as a 2-hour intravenous infusion for 5 days (days 1 to 5). Of 60 patients, 29 (48%) had secondary AML, 30 (50%) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25%]), and 11 (21%) showed FLT3 abnormalities. The overall response (OR) rate was 60% (52% CR, 8% CRp). Four patients (7%) died during induction. Adverse events were mainly grade 2 or lower and included diarrhea, nausea, vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-related facial flushing and headaches. Myelosuppression was common. Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation.

UR - http://www.scopus.com/inward/record.url?scp=33745586575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745586575&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-08-3294

DO - 10.1182/blood-2005-08-3294

M3 - Article

C2 - 16403905

AN - SCOPUS:33745586575

VL - 108

SP - 45

EP - 51

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -